Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit ...
Jan 20, 2023
0
4